drugset / Trial / NCT03176693

Preoperative Alpha Blockade for Pheochromocytoma

NCT03176693

Phase 3 Completed 39 enrolled University of California, Los Angeles
RandomizedParallel-groupOpen-labelTreatment

Summary

Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and mortality. Phenoxybenzamine is a non-selective alpha blocker that is significantly more expensive and is associated with increased adverse effects in comparison with selective alpha blockers such as doxazosin. Retrospective studies show minimal differences in hemodynamic instability and no differences in postoperative morbidity and mortality between selective vs. non-selective alpha blockers. This study is a randomized controlled trial that will compare hemodynamic instability, morbidity, mortality, cost, and quality of life between patients blocked with phenoxybenzamine vs. doxazosin.

Timeline

Start
2017-05-05
Primary completion
2020-01-31
Completion
2021-10-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxazosin Small molecule 1 mg Oral
Comparator Phenoxybenzamine Small molecule 10 mg Oral